Company
Valo Therapeutics
- Biotech
- Location:
- Helsinki, Finland
Description
Valo Therapeutics develops the PeptiCRAd oncolytic immunotherapy program, coating oncolytic and non-replicating viral vectors with disease-specific peptides to elicit enhanced T-cell responses for cancer treatment and rapidly adaptable, disease-specific therapies.
Valo Therapeutics is located in the Helsinki ecosystem.
Related
NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
21st.BIO21st.BIO A/S provides precision fermentation technology for proteins and peptides, using microbial strains, fermentation processes, and…
3H Biomedical3H Biomedical supplies primary human and animal cell-based products, RNA, DNA, assays and culture media for life science research, drug…
AbbelightAbbelight provides an integrated bioimaging workflow combining advanced microscopy and nanoscopy platforms, ready-to-use reagents, and NEO…
Ability PharmaAbility Pharma develops oral targeted anticancer compounds that induce cytotoxic autophagy in cancer cells and advances clinical-stage…
- ACD PharmaACD Pharma develops bacteriophage-based biocontrol products and technologies for preventing and treating bacterial infections, with…
AciesBioAciesBio provides microbial biotech services for strain engineering, scale-up process design, fermentation-broth processing, contract…
ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
Actival SAActival SA develops patient-specific active dental appliances and 3D-printed dental products that integrate patented microchannel…